Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

References

• Shahin OA, Ravandi F. Myeloid sarcoma. Curr Opin Hematol. 2020;27(2):88–94.
   PubMed Web of Science ®Google Scholar
• Bakst R, Powers A, Yahalom J. Diagnostic and therapeutic considerations for extramedullary leukemia. Curr Oncol Rep. 2020;22(7):75.
   PubMed Web of Science ®Google Scholar
• Stölzel F, Lüer T, Löck S, et al. The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial. Haematologica. 2020;105(6):1552–1558.
   PubMed Web of Science ®Google Scholar
• Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–3793.
   PubMed Web of Science ®Google Scholar
• Avni B, Rund D, Levin M, et al. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. Hematol Oncol. 2012;30(1):34–40.
   PubMed Web of Science ®Google Scholar
• Frietsch JJ, Hunstig F, Wittke C, et al. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant. 2021;56(1):101–109.
   PubMed Web of Science ®Google Scholar
• Szomor A, Passweg JR, Tichelli A, et al. Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma (chloroma) after allogeneic bone marrow transplantation. Ann Hematol. 1997;75(5–6):239–241.
   PubMed Web of Science ®Google Scholar
• Chang H, Brandwein J, Yi Q-L, et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004;28(10):1007–1011.
   PubMed Web of Science ®Google Scholar
• Breccia M, Mandelli F, Petti MC, et al. Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 2004;28(11):1165–1169.
   PubMed Web of Science ®Google Scholar
• Eshghabadi M, Shojania AM, Carr I. Isolated granulocytic sarcoma: report of a case and review of the literature. J Clin Oncol. 1986;4(6):912–917.
   PubMed Web of Science ®Google Scholar
• Stolzel F, Steudel C, Oelschlagel U, et al. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann Hematol. 2010;89(7):653–662.
   PubMed Web of Science ®Google Scholar
• Pui MH, Fletcher BD, Langston JW. Granulocytic sarcoma in childhood leukemia: imaging features. Radiology. 1994;190(3):698–702.
   PubMed Web of Science ®Google Scholar
• Campo E, Harris NL, Pileri SA, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon France: IARC WHO Classification of Tumours; 2017.
   Google Scholar
• Slusarenko da Silva Y, Naclério-Homem MDG. Myeloid sarcoma on the temporal region before the onset of the acute myeloid leukemia: an extremely rare case report. Oral Maxillofac Surg. 2020;24(2):251–254.
   PubMed Web of Science ®Google Scholar
• Dalland JC, Meyer R, Ketterling RP, et al. Myeloid sarcoma with CBFB-MYH11 fusion (inv(16) or t(16;16)) prevails in the abdomen. Am J Clin Pathol. 2020;153(3):333–341.
   PubMed Web of Science ®Google Scholar
• Taga T, Imamura T, Nakashima K, et al. Clinical characteristics of pediatric patients with myeloid sarcoma without bone marrow involvement in Japan. Int J Hematol. 2018;108(4):438–442.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang H, Nong W, et al. Isolated intracranial myeloid sarcoma mimicking malignant lymphoma: a diagnostic challenge and literature reviews. Onco Targets Ther. 2020;13:6085–6092.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Kantarjian HM, Wen S, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008;113(6):1370–1378.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Kantarjian HM, Estey E, et al. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003;17(6):1100–1103.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Vol. 2. Lyon, France: IARC; 2017.
   Google Scholar
• Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia classification. Am J Clin Pathol. 2003;119(5):672–680.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen J, Borthakur G, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017;123(3):426–435.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Blood RK-S. 2019. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Available from: ashpublications.org
   Google Scholar
• Warren M, Luthra R, Yin CC, et al. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012;25(10):1405–1412.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Wang F, Morita K, et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018;9(1):1–12.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Kaur V, Swami A, Alapat D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018;23(1):17–24.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336.
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer. 2002;94(6):1739–1746.
   PubMed Web of Science ®Google Scholar
• Movassaghian M, Brunner AM, Blonquist TM, et al. Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma. 2015;56(6):1698–1703.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:721–749.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Nishii K, Sakakura M, et al. Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature. Hematol J. 2004;5(1):84–89.
   PubMedGoogle Scholar
• Alvarez P, Navascués CA, Ordieres C, et al. Granulocytic sarcoma of the small bowel, greater omentum and peritoneum associated with a CBFβ/MYH11 fusion and inv(16) (p13q22): a case report. Int Arch Med. 2011;4(1):3.
   PubMedGoogle Scholar
• Dalland JC, Meyer R, Ketterling RP, et al. Myeloid sarcoma with CBFB-MYH11 fusion (inv(16) or t(16;16)) prevails in the abdomen. Am J Clin Pathol. 2019;21:333–341.
   Google Scholar
• Hagemeijer A, Hählen K, Sizoo W, et al. Translocation (9;11)(p21;q23) in three cases of acute monoblastic leukemia. Cancer Genet Cytogenet. 1982;5(2):95–105.
   PubMedGoogle Scholar
• Miura I, Nishinari T, Hashimoto K, et al. Translocation (8;17)(p21;q21), a possible variant of t(15;17), in acute promyelocytic leukemia. Cancer Genet Cytogenet. 1994;72(1):75–77.
   PubMedGoogle Scholar
• Douet-Guilbert N, Morel F, Le Bris M-J, et al. Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation. Leuk Lymphoma. 2005;46(1):143–146.
   PubMed Web of Science ®Google Scholar
• Choi M, Jeon YK, Sun C-H, et al. RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J. 2018;8(5):43–44.
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278.
   PubMed Web of Science ®Google Scholar
• O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors. Pharmacol Res. 2019;139:503–511.
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143–153.
   PubMed Web of Science ®Google Scholar